Clinical Trials Browser

INDUSTRY × Carcinoma, Non-Small-Cell Lung × L-BLP25 × Clear all

NCT02049151 2017-08-23

START2

Phase 3 Terminated

35 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT01731587 2017-02-28

FINGERPRINT

Phase 1 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT01015443 2016-10-26

INSPIRE

Phase 3 Terminated

285 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT01423760 2016-10-06

Common Safety Follow-up Trial of Tecemotide (L-BLP25)

Phase NA Terminated

27 enrolled 7 charts

Plasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Multiple Myeloma

NCT00409188 2015-11-20

START

Phase 3 Completed

1,513 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT00157209 2015-11-18

Phase 2b Randomized Controlled Study of Tecemotide (L-BLP25) for Immunotherapy of NSCLC (Non-Small Cell Lung Cancer)

Phase 2 Completed

171 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00960115 2015-10-21

Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy

Phase 1/2 Completed

178 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT00157196 2015-08-18

Safety Study of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease

Phase 2 Completed

22 enrolled 6 charts

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms